Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Sdg Inc. maintains 1 pending office action in the Biotechnology & Pharmaceuticals sector. The portfolio's current activity is limited to 1 distinct examiner working within 1 distinct art unit. This structure reflects a focused prosecution strategy with no current diversification across different examination groups. For a company in the biotechnology field, this concentration suggests a very specific application of their technology currently under review.
RONEY, CELESTE A is identified as the busiest examiner, handling 1 pending office action. Because this single examiner manages the only active office action, the immediate prosecution outcomes for the company depend entirely on this individual's review. The presence of only 1 pending office action indicates a low volume of active correspondence with the patent office at this time. Practitioners should prepare for a highly individualized prosecution process, as the lack of other pending matters means there are no parallel cases to provide additional data points. The 1 distinct art unit involved further reinforces the narrow scope of the company's current patent office engagement.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RONEY, CELESTE A | 1 | 63.0% | +17.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18321429 | LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS | RONEY, CELESTE A | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18321429 | LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS | RONEY, CELESTE A | 1612 | §112DP | Non-Final OA | — | Pending | May 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSdg Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Celeste A Roney has the most, with 1 of Sdg Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
